BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25055161)

  • 1. Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model.
    Sjögren E; Tammela TL; Lennernäs B; Taari K; Isotalo T; Malmsten LÅ; Axén N; Lennernäs H
    Mol Pharm; 2014 Sep; 11(9):3097-111. PubMed ID: 25055161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
    Tammela TL; Häggman M; Ladjevardi S; Taari K; Isotalo T; Lennernäs H; Weis J; von Below C; Wassberg C; Lennernäs B; Tolf A; Axén N; Gölander CG; Ahlström H
    J Urol; 2017 Dec; 198(6):1333-1339. PubMed ID: 28736321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
    Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
    J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.
    Schulz M; Schmoldt A; Donn F; Becker H
    Eur J Clin Pharmacol; 1988; 34(6):633-6. PubMed ID: 3169114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
    Zuo Z; Tam YK; Diakur J; Wiebe LI
    J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
    Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB
    J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
    Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients.
    Klotz L; Grudén S; Axén N; Gauffin C; Wassberg C; Bjartell A; Giddens J; Incze P; Jansz K; Jievaltas M; Rendon R; Richard PO; Ulys A; Tammela TL
    Eur Urol Focus; 2022 Jan; 8(1):112-120. PubMed ID: 33583762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food.
    Chen C; Cowles VE; Hou E
    J Clin Pharmacol; 2011 Mar; 51(3):346-58. PubMed ID: 20484610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of in vitro release models in formulation development and quality control of parenteral depots.
    Larsen C; Larsen SW; Jensen H; Yaghmur A; Ostergaard J
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1283-95. PubMed ID: 19941410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nomogram to predict the best biological half-life values for candidates for oral prolonged-release formulations.
    Zhou M; Notari RE
    J Pharm Sci; 1996 Aug; 85(8):791-5. PubMed ID: 8863265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for prostate cancer patients].
    Harano M; Kano M; Hida T; Fujisawa Y; Kano M
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):377-80. PubMed ID: 15045944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance.
    Weinling E; McDougall S; Andre F; Bianchetti G; Dubruc C
    Fundam Clin Pharmacol; 2006 Aug; 20(4):397-403. PubMed ID: 16867025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.